Polyneuropathy associated with anti-MAG IgM antibodies

Mazen M Dimachkie MD (

Dr. Dimachkie, Director of the Neuromuscular Disease Division and Executive Vice Chairman for Research Programs, Department of Neurology, The University of Kansas Medical Center, received honorariums from ArgenX, Cello, Corbus, CSL-Behring, EcoR1, Kezar, Momenta, NuFactor, Octapharma, Orphazyme, RMS Medical, Sanofi Genzyme, Shire Takeda, Spark Therapeutics, and Ra Pharma/UCB Biopharma for speaking engagements or consulting work, and grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, Novartis, Sanofi Genzyme, Octapharma, Orphazyme, Sarepta Therapeutics, Shire Takeda, Spark, Ra Pharma/UCB Biopharma, Viromed and TMA.

Louis H Weimer MD, editor. (

Dr. Weimer of Columbia University has received consulting fees from Roche.

Originally released July 13, 1998; last updated January 5, 2021; expires January 5, 2024


The author reviews advances in the diagnosis and management of patients with anti-MAG neuropathy. Deposits of IgM antibodies can be detected in the small nerve fibers from glabrous skin biopsy. The author also comments on the elevated risk of malignant plasma cell dyscrasias. Patients with anti-MAG neuropathy, therefore, require serial hematologic work-up.

Historical note and terminology

Antimyelin associated glycoprotein antibodies were first described in 1980 in a patient with neuropathy and IgM monoclonal gammopathy (Latov et al 1980; Braun et al 1982). More than 200 patients with this syndrome subsequently have been described. Several studies have delineated the clinical, laboratory, electrodiagnostic, immunologic, pathologic, and therapeutic aspects of this condition (Latov et al 1988; Nobile-Orazio et al 1989; Ellie et al 1996; Chassande et al 1998; Nobile-Orazio et al 2000; Eurelings et al 2001; Gorson et al 2001).

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology